221 related articles for article (PubMed ID: 7525123)
1. Inverse correlation between insulin-like growth factor binding protein-1 and insulin in patients with acromegaly during treatment with the somatostatin analogue octreotide.
Fredstorp L; Werner S; Bang P; Hall K
Clin Endocrinol (Oxf); 1994 Oct; 41(4):495-501. PubMed ID: 7525123
[TBL] [Abstract][Full Text] [Related]
2. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
Ezzat S; Ren SG; Braunstein GD; Melmed S
J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
[TBL] [Abstract][Full Text] [Related]
3. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
[TBL] [Abstract][Full Text] [Related]
4. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients.
Juul A; Main K; Blum WF; Lindholm J; Ranke MB; Skakkebaek NE
Clin Endocrinol (Oxf); 1994 Jul; 41(1):85-93. PubMed ID: 7519529
[TBL] [Abstract][Full Text] [Related]
5. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
[TBL] [Abstract][Full Text] [Related]
6. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly.
de Herder WW; Uitterlinden P; van der Lely AJ; Hofland LJ; Lamberts SW
Eur J Endocrinol; 1995 Aug; 133(2):195-9. PubMed ID: 7544670
[TBL] [Abstract][Full Text] [Related]
7. Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex.
Barreca A; Cariola G; Ponzani P; Arvigo M; Foppiani L; Giordano G; Minuto F
Clin Endocrinol (Oxf); 1995 Feb; 42(2):161-7. PubMed ID: 7535670
[TBL] [Abstract][Full Text] [Related]
8. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action.
Ezzat S; Ren SG; Braunstein GD; Melmed S
J Clin Endocrinol Metab; 1992 Dec; 75(6):1459-63. PubMed ID: 1281485
[TBL] [Abstract][Full Text] [Related]
9. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study.
Hansen TB; Gram J; Bjerre P; Hagen C; Bollerslev J
Clin Endocrinol (Oxf); 1994 Sep; 41(3):323-9. PubMed ID: 7955439
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study.
Fredstorp L; Werner S
J Endocrinol Invest; 1993 Apr; 16(4):253-8. PubMed ID: 8514980
[TBL] [Abstract][Full Text] [Related]
11. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
12. Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency.
Skjaerbaek C; Frystyk J; Kaal A; Laursen T; Møller J; Weeke J; Jørgensen JO; Sandahl Christiansen J; Orskov H
Clin Endocrinol (Oxf); 2000 Jan; 52(1):25-33. PubMed ID: 10651750
[TBL] [Abstract][Full Text] [Related]
13. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
Riedel M; Günther T; von zur Mühlen A; Brabant G
Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
[TBL] [Abstract][Full Text] [Related]
14. Suppression of endogenous insulin secretion regulates the rapid rise of insulin-like growth factor binding protein (IGFBP)-1 levels following acute hypoglycaemia.
Cotterill AM; Holly JM; Amiel S; Wass JA
Clin Endocrinol (Oxf); 1993 Jun; 38(6):633-9. PubMed ID: 7687525
[TBL] [Abstract][Full Text] [Related]
15. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW
Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911
[TBL] [Abstract][Full Text] [Related]
16. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
Fredstorp L; Kutz K; Werner S
Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
[TBL] [Abstract][Full Text] [Related]
17. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
[TBL] [Abstract][Full Text] [Related]
18. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.
Grinspoon S; Clemmons D; Swearingen B; Klibanski A
J Clin Endocrinol Metab; 1995 Mar; 80(3):927-32. PubMed ID: 7533774
[TBL] [Abstract][Full Text] [Related]
19. Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects.
Fredstorp L; Harris A; Haas G; Werner S
J Clin Endocrinol Metab; 1990 Nov; 71(5):1189-94. PubMed ID: 2229278
[TBL] [Abstract][Full Text] [Related]
20. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects.
Hilding A; Brismar K; Degerblad M; Thorén M; Hall K
J Clin Endocrinol Metab; 1995 Sep; 80(9):2646-52. PubMed ID: 7545695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
